Clinical Efficacy and Safety of CD47 Monoclonal Antibody Combined With Azacitidine in the Treatment of Recurrent AML After Transplantation

NCT05266274 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

69

Enrollment

OTHER

Sponsor class

Conditions

Patients With Recurrent Acute Myelogenous Leukemia After Transplantation

Interventions

DRUG: CD47 monoclonal antibody

Sponsor

The First Affiliated Hospital of Soochow University